News
KTTAW
0.0066
+17.86%
0.0010
Weekly Report: what happened at KTTA last week (0601-0605)?
Weekly Report · 1d ago
Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
TipRanks · 06/02 11:30
Pasithea Therapeutics' PAS-004 Receives FDA Orphan Drug Designation For ALS
NASDAQ · 06/02 11:21
Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis
Benzinga · 06/02 11:08
Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
PUBT · 06/02 11:05
PASITHEA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION BY FDA OF PAS-004 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Reuters · 06/02 11:02
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Barchart · 06/02 06:02
Weekly Report: what happened at KTTA last week (0525-0529)?
Weekly Report · 06/01 09:25
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
TipRanks · 05/29 17:55
Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis
Benzinga · 05/29 17:52
Weekly Report: what happened at KTTA last week (0518-0522)?
Weekly Report · 05/25 09:26
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
TipRanks · 05/21 10:15
Weekly Report: what happened at KTTA last week (0511-0515)?
Weekly Report · 05/18 09:25
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Benzinga · 05/15 22:22
Weekly Report: what happened at KTTA last week (0504-0508)?
Weekly Report · 05/11 09:24
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
PUBT · 05/05 20:46
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
TipRanks · 05/04 23:03
Pasithea Therapeutics appoints chief medical officer
Seeking Alpha · 05/04 12:34
Pasithea Therapeutics Appoints Kartik Krishnan As CMO
NASDAQ · 05/04 11:37
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
TipRanks · 05/04 11:32
More
Webull provides a variety of real-time KTTAW stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.